Blood life - - Chromatography Online
Blood life

The Column

Conditions of acute and chronic anaemia that are the result of either a long-standing medical condition (sickle-cell anaemia) or surgical intervention (chemotherapy) often require the administration of blood transfusions to improve the capacity of the patient’s red blood cells to carry oxygen1. Red blood cell (RBC) populations have a short shelf life in storage as a result of biomechanical and biochemical changes that reduce the RBC functionality. This has an impact on the viability and therapeutic benefits of ex vivo RBC transfusions.

A group of investigators in Germany2 has identified a potential solution to this problem, identifying three so-called ‘biomarkers’ that could be used in the development of an assay determining the effect of storage on the functionality of RBC’s. Biomarkers are candidate proteins that can be identified with relative ease and efficiency, have specific physiological functions and specific localisation within a cell. Despite the simple structure and high availability of RBC’s, the high concentration of membrane proteins and intracellular haemoglobin present a complex analytical mixture.

The investigators observed changes in the RBC proteome over a time course of 42 days. 2D DIGE (2-D Fluorescence Difference Gel Electrophoresis) was used to quantitively measure changes in cytosolic proteins over the time course, providing a so-called ‘spot map’, where specific protein spots could be visualised to change over time. Selected protein spots were isolated by trypsin digestion, identified by liquid chromatography– mass spectrometry (LC–MS) and validated by western blotting (the detection of proteins within a gel with a specific antibody). Out of fourteen protein spots identified to be altered post storage, three proteins were selected as potential biomarkers for the monitoring of RBC ageing: transglutaminase 2, ß-actin and copper chaperone for superoxide dismutase.

The discovery of a change in the cytosolic proteome profile and the identification of potential biomarkers is an important step towards improving our understanding of blood storage methods. It may go some way to contributing to the development of specific assays for the measurement and therefore judgement of the therapeutic benefits of blood transfusions to critically ill patients.

1. UK Blood Transfusion & Tissue Transplantation Services: Transfusion Handbook. (www.transfusionguidelines.org.uk)

2. K. Walpurgis et al, Proteomics Journal (2012) DOI: 10.1002/pmic.201200280.

This story originally appeared in The Column. Click here to view that issue.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters
Global E-newsletters subscribe here:




 

LCGC COLUMNISTS 2014

Column Watch: Ron Majors, established authority on new column technologies, keeps readers up-to-date with new sample preparation trends in all branches of chromatography and reviews developments. LATEST: When Bad Things Happen to Good Food: Applications of HPLC to Detect Food Adulteration


Perspectives in Modern HPLC: Michael W. Dong is a senior scientist in Small Molecule Drug Discovery at Genentech in South San Francisco, California. He is responsible for new technologies, automation, and supporting late-stage research projects in small molecule analytical chemistry and QC of small molecule pharmaceutical sciences. LATEST: HPLC for Characterization and Quality Control of Therapeutic Monoclonal Antibodies


MS — The Practical Art: Kate Yu brings her expertise in the field of mass spectrometry and hyphenated techniques to the pages of LCGC. In this column she examines the mass spectrometric side of coupled liquid and gas-phase systems. Troubleshooting-style articles provide readers with invaluable advice for getting the most from their mass spectrometers. LATEST: Radical Mass Spectrometry as a New Frontier for Bioanalysis


LC Troubleshooting: LC Troubleshooting sets about making HPLC methods easier to master. By covering the basics of liquid chromatography separations and instrumentation, John Dolan is able to highlight common problems and provide remedies for them. LATEST: How Much Can I Inject? Part I: Injecting in Mobile Phase


More LCGC Columnists>>

LCGC North America Editorial Advisory Board>>

LCGC Europe Editorial Advisory Board>>

LCGC Editorial Team Contacts>>


Source: The Column,
Click here